Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Variants/Exon 19 Deletion

Exon 19 Deletion

CIViC ID: 133 · Gene: EGFR

Variant Summary

HGVS: ENST00000275493.2:c.2185_2283del
Variant Type(s): inframe_deletion
Evidence Items: 18

Evidence Level Distribution

Level A: 2Level B: 12Level C: 1Level D: 3

Evidence Items

Showing CIViC evidence rows where gene = EGFR and variant = Exon 19 Deletion.

Level	Type	Direction	Significance	Disease	Drugs	Rating
A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	5
A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	5
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	4
B	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Anti-PD1 Monoclonal Antibody	4
B	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Anti-PD-L1 Monoclonal Antibody	4
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Dacomitinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	3
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	2
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	2
C	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	0